» Articles » PMID: 22192426

Biological and Functional Characteristics of a Novel Low-molecular Weight Antagonist of Glucose-dependent Insulinotropic Polypeptide Receptor, SKL-14959, in Vitro and in Vivo

Overview
Specialty Endocrinology
Date 2011 Dec 24
PMID 22192426
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: We recently discovered a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, SKL-14959. GIP plays a role in the glucose and lipid metabolism, and is associated with obesity and insulin resistance. Therefore, we aimed to ascertain the inhibitory potency and glucose and lipid metabolism of SKL-14959.

Methods: SKL-14959 was evaluated for its binding affinity to each GIP, glucagon-like peptide-1 (GLP-1) and glucagon receptors by each labelled and non-labelled ligand; GIP-stimulated cyclic AMP (cAMP) production in CHO cells expressing human GIP receptor in vitro. Oral and intraperitoneal glucose tolerance tests (OGTT and IPGTT) were performed to examine the insulinotropic effect on endogenous and exogenous GIP. Oil tolerance tests were also conducted to examine the lipid metabolism and the postheparin plasma lipase activity, lipoprotein lipase (LPL) and hepatic lipase (HL).

Result: SKL-14959 selectively bound to GIP receptor and inhibited GIP-stimulated cAMP production with the Ki value of 55 nM and an IC(50) value of 2.9 µM, respectively. SKL-14959·Na significantly increased blood glucose levels, inhibited insulin secretion in OGTT and inhibited the plasma glucose lowering of exogenous GIP in IPGTT. Furthermore, SKL-14959 increased plasma triacylglycerol (TG) levels as well as suppressed the postheparin plasma lipase activity in an oil load test.

Conclusion: These data indicate that SKL-14959 is distinguished in the physiological phenotype of GIP following direct binding to the receptor.

Citing Articles

Does glucose-dependent insulinotropic polypeptide receptor blockade as well as agonism have a role to play in management of obesity and diabetes?.

Lafferty R, Flatt P, Gault V, Irwin N J Endocrinol. 2024; 262(2).

PMID: 38861364 PMC: 11301427. DOI: 10.1530/JOE-23-0339.


GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice.

Nakamura T, Tanimoto H, Okamoto M, Takeuchi M, Tsubamoto Y, Noda H Diabetes Metab Syndr Obes. 2021; 14:1095-1105.

PMID: 33727843 PMC: 7955685. DOI: 10.2147/DMSO.S297353.


The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.

Wilson J, Nikooienejad A, Robins D, Roell W, Riesmeyer J, Haupt A Diabetes Obes Metab. 2021; 22(12):2451-2459.

PMID: 33462955 PMC: 7756479. DOI: 10.1111/dom.14174.


Gastric inhibitory polypeptide receptor antagonist, SKL-14959, suppressed body weight gain on diet-induced obesity mice.

Nakamura T, Tanimoto H, Mizuno Y, Okamoto M, Takeuchi M, Tsubamoto Y Obes Sci Pract. 2018; 4(2):194-203.

PMID: 29670757 PMC: 5893465. DOI: 10.1002/osp4.164.


Gut hormone polyagonists for the treatment of type 2 diabetes.

Brandt S, Gotz A, Tschop M, Muller T Peptides. 2018; 100:190-201.

PMID: 29412819 PMC: 5805859. DOI: 10.1016/j.peptides.2017.12.021.